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Fetal haemoglobin response to hydroxycarbamide treatment
and sar1a promoter polymorphisms in sickle cell anaemia
Reactivation of fetal haemoglobin (HbF) expression in adult
life could provide an effective therapeutic approach for
patients with haemoglobinopathies and thalassaemias. Among
HbF induction agents, hydroxycarbamide (HC) has been
successfully used to treat sickle cell disease (SCD) and selected
thalassaemia syndromes (Rodgers et al, 1990; Zeng et al, 1995;
Fucharoen et al, 1996). Hydroxycarbamide is believed to exert
its beneﬁcial effects in SCD via a variety of mechanisms,
including augmented HbF synthesis by erythroid regeneration
or NO-related increases in soluble guanylate cyclase activity
and cyclic guanidine monophosphate (cGMP) that stimulate
HBG expression (Cokic et al, 2003). Additional mechanisms
may also include myelosuppression with a reduction in
circulating neutrophils, increased erythrocyte water content,
modiﬁed erythrocyte endothelial cell interactions and altered
vascular tone by increasing NO bioavailability (Okpala, 2005).
Many patients treated with HC increase HbF levels from
baseline, with wide variability in the magnitude of this
response. The underlying reasons for this spectrum of HC
responsiveness are poorly understood (Steinberg et al, 1997;
Bakanay et al, 2005).
Presently, a major research priority is the identiﬁcation of
genetic variants underlying both human diseases and differ-
ences in pharmacological responsiveness to drugs (Collins
et al, 2003). In SCD, this paradigm is being applied to
elucidate the pathogenesis of vaso-occlusive and vascular
complications and to develop individualized SCD therapies
(Steinberg, 2005). Genetic variants in drug-metabolizing
enzymes, transporters or targets could potentially inﬂuence
the efﬁcacy or toxicity of drugs used in SCD. The HC-induced
small guanosine triphosphate (GTP)-binding protein, secre-
tion-associated and RAS-related (SAR) protein has recently
been shown to play a pivotal role in HBG induction by causing
cell apoptosis and G1/S-phase arrest by reduction of
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The hydroxycarbamide (HC)-inducible small guanosine triphosphate (GTP)-
binding protein, secretion-associated and RAS-related (SAR) protein has
recently been shown to play a pivotal role in HBG induction and erythroid
maturation by causing cell apoptosis and G1/S-phase arrest. Our preliminary
analysis indicated that HC inducibility is transcriptionally regulated by
elements within the SAR1A promoter. This study aimed to assess whether
polymorphisms in the SAR1A promoter are associated with differences Hb F
levels or HC therapeutic responses among sickle cell disease (SCD) patients.
We studied 386 individuals with SCD comprised of 269 adults treated with or
without HC and 117 newborns with SCD identiﬁed from a newborn
screening program. Three previously unknown single nucleotide
polymorphisms (SNPs) in the upstream 5¢UTR ()809 C>T, )502 G>T and
)385 C>A) were signiﬁcantly associated with the fetal haemoglobin (HbF)
response in Hb SS patients treated with HC (P <0 Æ05). In addition, four
SNPs (rs2310991, )809 C>T, )385 C>A and rs4282891) were signiﬁcantly
associated with the change in absolute HbF after 2 years of treatment with
HC. These data suggest that variation within SAR1A regulatory elements
might contribute to inter-individual differences in regulation of HbF
expression and patient responses to HC in SCD.
Keywords: hydroxycarbamide, SAR1A, sickle cell disease, fetal haemoglobin,
single nucleotide polymorphism.
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related kinase (ERK) phosphorylation with increased p21 and
GATA-2 expression (Tang et al, 2005).
SAR1A belongs to the small GTPase superfamily and
encodes a GTP-binding protein SAR1a. This protein plays a
key role in initializing transport from the endoplasmic
reticulum (ER) to the Golgi apparatus. The localization of
SAR1A in the endoplasmic reticulum and its association with
HBG expression demonstrated in our recent study suggest that
SAR1A also plays a special role in haemoglobin regulation
(Tang et al, 2005). However, the precise pathway(s) through
which SAR1A regulates HBG remain unknown. SAR1A may
increase the transport of membrane-bound transcription
factor precursors from the ER to the Golgi. The proteolytic
cleavage of the precursor proteins in the Golgi activate
cytosolic fragments that enter the nucleus and regulate
erythroid-speciﬁc transcription factors, such as GATA, even-
tually modulating HBG expression. Moreover, previous studies
have illuminated a pivotal role of the p38 mitogen-activated
protein kinase (MAPK) pathway during GTP-mediated ery-
throid differentiation of K562 cells with the accumulation of
HBG mRNA (Osti et al, 1997; Moosavi et al, 2007). Activators
of the soluble guanylate cyclase (sGC) and protein kinase G
(PKG) pathways have been implicated in the regulation of
HBG expression in both erythroleukemic cells and in primary
erythroblasts (Ikuta et al, 2001). Expression of HBG and the
sGC alpha subunit are correlated, indicating that GTP-binding
proteins may participate in HBG induction.
Preliminary data from our study indicated that HC induc-
ibility is transcriptionally regulated and localized to elements
in the SAR1A promoter. Accordingly, we hypothesized that
DNA sequence variation within the SAR1A promoter might
explain differences in individual responses to HC therapy.
To test this hypothesis, we identiﬁed the single nucleotide
polymorphism (SNPs) in the SAR1A promoter by DNA
sequencing and examined these variants in an association
study of sickle cell anaemia patients treated with HC.
Materials and methods
Subjects
DNA samples and laboratory data were from unrelated
individuals with SCD who enrolled in a Sickle Cell Pulmonary
Hypertension Screening Study at the National Institutes of
Health (NIH) and Howard University (ClinicalTrials.gov
Identiﬁer: NCT00011648). The study had enrolled 282 subjects
as of December, 2005, of which 269 had sufﬁcient clinical data
for inclusion in the present study (Taylor et al, 2008). All
subjects were at least 18 years of age and provided written
informed consent for participation in this Institutional Review
Board (IRB) approved protocol. Cases and controls were
deﬁned as adults with SCD who were treated with or without
HC respectively. Additionally, 32 of these 269 subjects had
quantitative high performance liquid chromatography (HPLC)
HbF measurements and other laboratory values determined
prior to and during HC therapy. The mean length of follow-up
evaluation for patients with HbF measured at the end of the
study was 21 months (maximum, 33 months; minimum,
8 months). DNA was also available from 117 newborns
identiﬁed with SCD by a state newborn screening program
during a single calendar year, where DNA was collected
anonymously with prospective exemption from IRB review.
Polymerase chain reaction (PCR) and DNA sequencing
A 2265 base pair fragment which included the SAR1A
upstream promoter region, exon 1, and a portion of intron 1
was ampliﬁed using gene-speciﬁc primers: forward primer,
5¢ ATGTGCACAACAATGCCTGT 3¢; reverse primer, 5¢ GAA-
ACTGTTATCCGGCCCAG 3¢. The PCR conditions were an
initial denaturation at 95 C for 3 min, followed by 35 cycles at
95 C for 45 s, 56 C for 1 min and 2 min at 72 C. Finally an
additional elongation step was carried out at 72 C for 7 min.
The PCR products were puriﬁed using QIAquick PCR
puriﬁcation kit (Qiagen, Valencia, CA, USA). Puriﬁed PCR
products were directly sequenced in both directions by using
Big Dye chemistry (Applied Biosystems, Foster City, CA,
USA). The BioEdit and Clustal W programs were used to
multiple align individual sequences with the reference
sequence (GenBank accession number: NT008583 or March,
2006 assembly hg18: chr10:71599909-71602173).
Statistical analysis
Comparisons of genotype and allele frequencies between cases
and controls were carried out using chi-squared tests of
association. Three genetic models (dominant, codominant and
recessive) for modulation of response to HC treatment were
tested. Genotype speciﬁc risks were estimated as odds ratio
(OR) with 95% conﬁdence intervals (95% CI). Multiple
logistic regression (JMP 6.0.3) was used to investigate the
association between individual SNPs and the change in HbF
level after HC treatment. Haplotypes were determined using
Phase 2.1 (Stephens & Donnelly, 2003). Probability differences
of P <0 Æ05 were considered as statistically signiﬁcant without
additional correction for multiple comparisons.
Results
Of 282 enrolled adults at NIH, 13 patients were excluded
because of incomplete data. The majority was Hb SS (202
cases, 71Æ6%), 44 haemoglobin SC (15Æ6%), 16 sickle b
+-
thalassaemia (5Æ7%), 4 sickle b
0-thalassaemia (1Æ4%), two
haemoglobin SD (0Æ7%), one haemoglobin SOArab (0Æ4%)
and two with incompletely characterized sickle b-thalassaemia
(0Æ7%). The presence of coincident a-thalassaemia (a
3Æ7
deletion) was also determined for 260 SCD subjects (92Æ2%,
n = 282): 179 (68Æ8%) with aa/aa, 73 (28Æ1%) with )a/aa,
seven (2Æ7%) with )a/)a and one (0Æ4%) with aaa/aa.N o
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4Æ2 deletions were detected (89Æ4%, n = 252 out of total 282)
(Taylor et al, 2008).
In order to determine the pattern of mutation and
polymorphism across putative HC responsive regulatory
elements in SCD patients, we designed sequence-speciﬁc
primers corresponding to a 2Æ3 kb fragment of SAR1A on
chromosome 10 which was completely sequenced in all
subjects. Twenty DNA sequence variants, including two
insertion/deletion polymorphisms and nine that have been
previously reported in dbSNP (http://www.ncbi.nlm.nih.gov/
SNP/index.html), were identiﬁed among a total of 386
patients, consisting of 269 adults at NIH and 117 newborns
with SCD. Fourteen variants were within the upstream
promoter region, four SNPs were in the 5¢UTR encoded
within exon 1 (+14 T>A, rs3812693, +31 T>C and rs3812692),
and 2 SNPs were within the ﬁrst intron (rs4282891 and intron
1 + 140 C>G). Using Phastcons genomic sequence alignments
from 17 vertebrate species including Homo sapiens (http://
www.genome.ucsc.edu; May, 2004 hg17 assembly), we identi-
ﬁed phylogenetically conserved blocks of sequence across this
2Æ3 kb region of SAR1A. Four SNPs ()30 C>G, +14 T>A,
rs4282891 and intron 1 + 140 C>G) corresponded to highly
conserved non-coding nucleotide sites (Phastcons scores >
0Æ4), which is strongly suggestive of an increased likelihood
that these SNPs represent functional variants.
When SAR1A sequence data were compared between NIH
subjects and the newborn SCD cohort, differences in genotype
frequency were observed for rs2310991 in the upstream
promoter region [Odds ration (OR) = 1Æ9, 95% CI = 1Æ1)3Æ2,
P =0 Æ009] and +31 T>C in the 5¢UTR [OR 9Æ8( 1 Æ3-73Æ9); 95%
CI; P <0 Æ001] (data not shown).
Individual SAR1A variants were then analysed for associa-
tion with HbF levels, expressed as percentage of total
haemoglobin (%) or as absolute HbF (g/l), among 176 adults
with homozygous SCD (SS) treated with or without HC (69
cases vs. 107 cases). Three SNPs in the upstream promoter
region ()809 C>T, )502 G>T and )385 C>A) were signiﬁ-
cantly associated with higher percentage HbF under a
co-dominant genetic model even after statistical correction
(Table I). The major allele frequency of )809 C>T,
)502 G>T and )385 C>A were 0Æ93, 0Æ98 and 0Æ96 respec-
tively. When the analysis was repeated using absolute HbF
concentration as a clinical endpoint between HC cases and SS
controls, only one of these three markers showed evidence for
an association (SNP )502 G>T; data not shown). None of the
20 variants were associated with total haemoglobin levels as the
outcome measure between cases and controls (data not
shown).
In addition, 32 of the Hb SS subjects had prospective,
regular clinical evaluations including quantitative HbF
Table I. SNPs associated with a higher percent HbF (%HbF) with hydroxycarbamide treatment.
SNP rs Number Ch 10 map position Dominant Codominant Recessive Major allele frequency
)1377 (G>T)* rs2310991 71601652 0Æ0027  0Æ0218 0Æ1369 0Æ45
)809 (C>T) rs76901216 71601084 0Æ0413 0Æ0008  ND 0Æ93
)743 (G>A)* rs10999169 71601018 0Æ0418 0Æ0108 0Æ0079 0Æ77
)605/)606 (–>T)* rs11438971 71600880/71600879 ND ND 0Æ0231 0Æ01
)502 (G>T) rs76901217 71600777 0Æ0300 2Æ1266E-07  ND 0Æ98
)460 (C>G) rs76901218 71600735 0Æ0084 0Æ0129 ND 0Æ98
)432 (T>–)* rs11284333 71600707 0Æ0199 ND 0Æ0319 0Æ61
)420 (TTTT>–)* rs10577419 71600699 0Æ0310 ND 0Æ0117 0Æ60
)417 (T>–)* rs5785963 71600692 0Æ0258 ND 0Æ0140 0Æ61
)396 (T>C) rs76901219 71600671 0Æ0264 ND ND 0Æ98
)385 (C>A) rs76901220 71600660 0Æ0344 1Æ0610E-07  ND 0Æ96
)372 (G>A) rs76901221 71600647 0Æ0161 0Æ0833 0Æ0027  0Æ89
)45 (G>A) rs76901222 71600320 0Æ0348 0Æ5382 ND 0Æ98
)30 (C>G) rs76901223 71600305 0Æ0264 ND ND 1Æ00
+14 (T>A)  rs76901224 71600262 0Æ0288 ND ND 1Æ00
+27 (C>A)*  rs3812693 71600249 0Æ0146 0Æ0284 ND 0Æ98
+31 (T>C)  rs76901225 71600245 0Æ0159 0Æ6734 ND Æ95
+68 (C>T)*  rs3812692 71600208 0Æ0228 ND ND 0Æ99
Intron 1 + 100 (G>A)* rs4282891 71600075 0Æ0193 0Æ8913 ND 0Æ98
Intron 1 + 140 (C>G) rs76901226 71600035 0Æ0267 ND ND 0Æ99
*Previously reported in dbSNP.
 Present within the 5¢ UTR.
 Signiﬁcant P-value after Bonforoni correction.
Bold: SNP with P-value £ 0Æ05.
ND, not determined.
Major allele frequency was calculated from genotype frequency of Hb SS patients.
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this patient subset was analysed, only rs2310991 was signiﬁ-
cantly associated with the change in the percentage of HbF.
However, four markers (rs2310991, )809 C>T, )385 C>A and
rs4282891) were signiﬁcantly associated with the change of
absolute HbF concentration. The most statistically signiﬁcant
P-value for an association was at rs4282891 (P =0 Æ0012),
which is phylogenetically conserved in vertebrates (Phastcons
score = 0Æ5984) and present intron 1 of SAR1A (Table II).
Considering all 20 markers, there were 64 total haplotypes
including seven common haplotypes (>5% frequency) span-
ning 1617 nucleotides. Signiﬁcant individual associations
observed for markers )809 C>T, )502 G>T, and )385 C>A
in the overall population and the 32 prospective follow-up
subjects reﬂected a co-dominant haplotypic effect for the TGA
variant (n = 23, 4Æ6%) and CGC wild type (n = 447, 89Æ8%)
SAR1A promoter haplotypes.
Discussion
HC therapy in sickle cell anaemia increases the circulating HbF
concentration in most individuals, although a large proportion
of compliant patients experience either a complete failure to
respond or have a small, clinically insigniﬁcant increase in HbF
(Ma et al, 2007). Even among patients who are identiﬁed as
HC responders, the magnitude of HbF increase is variable
(Charache et al, 1995; ; Steinberg et al, 1997; Zimmerman
et al, 2004; Bakanay et al, 2005; Ma et al, 2007). Presently, the
underlying reason for this variability is not known (Steinberg
et al, 1997; Bakanay et al, 2005).
Our previous work identiﬁed a novel role of SAR1A in HBG
induction that is distinct from its previously established
protein-trafﬁcking function. SAR1A participates in HBG
expression and erythroid cell maturation after HC treatment
by regulating PI3 kinase/ERK and GATA-2/p21-dependent
signal transduction pathways (Tang et al, 2005). These results
led us to hypothesize that functional polymorphisms in
regulatory elements of HC inducible genes, like SAR1A,
modulate HbF levels or HC therapeutic responses. The present
study identiﬁed all of the common nucleotide variants across a
2Æ3 kb region, which includes the promoter and ﬁrst exon of
SAR1A, including a subset of markers that are associated with
either differences in HbF levels or change in HbF levels in
sickle cell anaemia patients treated with HC. Individual
associations with higher HbF concentration in HC-treated
patients were detectable under three different genetic models
(Table I), in addition to a more rigorous logistic regression
association analysis of a subset of prospectively treated patients
(Table II). Similar to our present ﬁndings in SAR1A, all of the
presently known SNP markers in HC inducible genes associ-
ated with higher HbF are located within either promoter
regions or the ﬁrst intron 1 of candidate genes (Ma et al,
2007). In the slightly larger population studied by Ma et al
(2007), variants in genes like FLT1, ARG2, HAO2 and NOS1
inﬂuenced HbF treatment response. Collectively, these associ-
ation studies suggest that a speciﬁc transcriptionally regulated
Table II. SNPs associated with a signiﬁcant
change in HbF levels after 2 years of hydroxy-
carbamide treatment in 32 adults with sickle cell
anaemia.
SNP rs Number Ch10 map position % HbF Absolute HbF
)1377 (G>T)* rs2310991 71601652 0Æ0229 0Æ0338
)809 (C>T) rs76901216 71601084 0Æ0584 0Æ0270
)743 (G>A)* rs10999169 71601018 0Æ0806 0Æ2591
)605/)606 (–>T)* rs11438971 71600880/71600879 0Æ0720 0Æ1514
)502 (G>T) rs76901217 71600777 0Æ3569 0Æ9125
)460 (C>G) rs76901218 71600735 0Æ8546 0Æ8040
)432 (T>–)* rs11284333 71600707 0Æ8719 0Æ4418
)420 (TTTT>–)* rs10577419 71600699 0Æ5861 0Æ7434
)417 (T>–)* rs5785963 71600692 0Æ6116 0Æ4440
)396 (T>C) rs76901219 71600671 0Æ5035 0Æ4804
)385 (C>A) rs76901220 71600660 0Æ0584 0Æ0270
)372 (G>A) rs76901221 71600647 0Æ6441 0Æ3167
)45 (G>A) rs76901222 71600320 0Æ1490 0Æ1560
)30 (C>G) rs76901223 71600305 ND ND
+14 (T>A)  rs76901224 71600262 0Æ3151 0Æ9402
+27 (C>A)*  rs3812693 71600249 ND ND
+31 (T>C)  rs76901225 71600245 0Æ3483 0Æ9676
+68 (C>T)*  rs3812692 71600208 ND ND
Intron 1 + 100 (G>A)* rs4282891 71600075 0Æ2078 0Æ0012
Intron 1 + 140 (C>G) rs76901226 71600035 0Æ4313 0Æ8147
*Previously reported in dbSNP.
 Present within the 5¢ UTR.
Bold: SNP with P-value £ 0Æ05.
ND, not determined.
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that genetic variants within regulatory elements of these genes
could modulate this response.
Comparative sequence analysis and cross-species conserva-
tion have previously been used to identify putative genes and
regulatory elements in small genomic regions, suggesting that
this is a viable approach for hypothesis generation and ﬁne
mapping functional variants underlying genetic association
studies (Pennacchio et al, 2001; Woolfe et al, 2005). Conserved
sites within a 2Æ3 kb region of SAR1A were identiﬁed using the
University of California Santa Cruz phastCons algorithm,
which is based on a two state phylogenetic hidden Markov
model that determines a likelihood ratio for conservation at a
single nucleotide site across vertebrates (Siepel et al, 2005). We
identiﬁed four variants, including three previously unknown
markers ()30 C>G, +14 T>A, rs4282891 and intron 1 + 140
C>G), occurring at highly conserved SAR1A nucleotides. Thus,
these variants are priority candidates for additional study to
evaluate their role in regulating SAR1A transcription, poten-
tially such using novel methods as high throughput transcrip-
tional proﬁling for cloned promoter haplotypes in response to
therapeutic agents like HC (Idelman et al, 2007).
SAR1A joins an expanding list of candidate loci including
the genes listed above and regions of chromosomes 6q, 8q and
Xp that might modulate HbF expression or HC responses. In
humans, there are two SAR genes; SAR1A on chromosome 10
and SAR1B on chromosome 5. Although, these paralogs share
high degree of amino acid sequence homology (89Æ4%), their
expression patterns are distinct. SAR1A is expressed ubiqui-
tously, most abundantly in prostate, thyroid and adrenal gland
while SAR1B has a tissue-speciﬁc pattern with moderate
expression in heart, liver, skeletal muscle and testis (He et al,
2002; Tang et al, 2005). These differences in expression
patterns suggest different biological roles in various tissues
and involvement in different human disease processes. Indeed,
SAR1B mutations cause lipid absorption disorders, such as
chylomicron retention disease (CMRD; MIM 246700) and
Anderson disease (MIM 607689). In contrast, SAR1A muta-
tions were not identiﬁed in either of these syndromes (Jones
et al, 2003). To date, there are no known human SAR1A
human mutations although this association study suggests that
some SNPs could subtly alter SAR1A expression or function.
Finally, others have also examined SAR1A polymorphisms
and haemolysis-driven phenotypes of SCD, such as leg ulcers,
but these studies have not demonstrated signiﬁcant associa-
tions (Nolan et al, 2006). Similarly in this study, there was no
association between SAR1A SNPs and pulmonary hypertension
(e.g. tricuspid regurgitant jet velocity >2Æ5 m/s, data not
shown), which is also believed to be a haemolysis-associated
complication of SCD. However, it is worthwhile to note that
the Nolan leg ulcer study evaluated SNPs (rs870801 in intron 1
and rs2271690 in intron 3) that are located approximately
10 kb pairs apart from one another within a 20Æ3 kb gene
(SAR1A). While these negative results suggest an unlikely role
for involvement of SAR1A in response to haemolysis in SCD,
neither study utilized high density, haplotype tagged markers
to interrogate this gene. Additional study of the role of this
gene in response to HC therapy and haemolysis are warranted
before ﬁrm conclusions can be made.
In conclusion, SAR1A polymorphisms might contribute to
the regulation of HbF expression and modulate patient
responses to HC in sickle cell anaemia. However, replication
in independent populations and targeted functional studies are
needed to conﬁrm the validity of these associations.
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